Description
Description
Sevoflurane is an inhaled general anesthetic featured with rapid induction and quick wake-up of patients. It has slight inhibition on circulation, little effect on liver and kidney function and a clear myocardial protective effect. Therefore, sevoflurane has now become the main inhaled anesthetic and is particularly suitable for patients with myocardial damage.
According to CRI’s analysis, in 1996, the sevoflurane of Abbott entered the Chinese market, but currently Abbott holds a very small market share. The approved imported sevoflurane also comes from Maruishi and MARUKO of Japan and Baxter of the United States. In 2007 and 2008, Chinese government approved the inhaled solution sevoflurane of Shanghai Hengrui Pharmaceuticals and Lunan Better Pharmaceutical to go public in China. Gradually, domestic sevoflurane dominates the Chinese market.
As the environmental pollution intensifies and the population ages, the demand for medical services is rapidly rising. The hospitalization increased from 115 million in 2008 to 266 million in 2019, with the CAGR up to 7.9%. Among them, one quarter of patients was hospitalized for surgery. The increasing amount of surgery boosts the demand for narcotic drugs.
According to CRI’s research, sales value of sevoflurane in the Chinese market rose from less than CNY 4 million in 2005 to CNY 82.8 million in 2007 and to CNY 723.4 million in 2019 and the CAGR is about 19.8% in 2007 to 2019.
According to CRI’s market research, the major market share holders in China are Shanghai Hengrui Pharmaceutical Co., Ltd., Maruishi, Baxter and Lunan Better Pharmaceutical Co., Ltd. In terms of sales value, Shanghai Hengrui Pharmaceutical holds the biggest market occupancy, which was about 66.4% in 2019.
According to CRI’s market research, in 2020, due to the COVID-19 epidemic, the number of surgeries in Chinese hospitals will decrease, so the sales of sevoflurane will also decrease accordingly. It is expected that from 2021 to 2024, the demand for sevoflurane in the Chinese market will show a recovery growth.
Topics Covered:
-Indication of sevoflurane
-Sales volume and value of sevoflurane in China 2015-2019
-Sales volume and value of sevoflurane in different regions of China 2015-2019
-Major sevoflurane manufacturers in the Chinese market
-Competition pattern of sevoflurane in China
-Sale price of sevoflurane in China
-Sale price of sevoflurane by manufacturers and regions in China
-Prospects of sevoflurane in China 2020-2024
-The impact of the COVID-19 outbreak on China’s sevoflurane market
